Join the club for FREE to access the whole archive and other member benefits.

David Rawlings

Director of Seattle Children's Center for Immunity and Immunotherapies

David J. Rawlings, MD, is chief in the Division of Immunology, overseeing the immunodeficiency clinic at Seattle Childrens Hospital. He is also director of the Center for Immunity and Immunotherapies leading the immunology research programs at Seattle Childrens Research Institute. Dr. Rawlings is professor of pediatrics and adjunct professor in the Department of Immunology at the University of Washington School of Medicine.

He earned his MD with honors from the University of North Carolina School of Medicine and completed a residency and chief residency in pediatrics at the University of California, San Francisco. He was an intramural research fellow at the NIH and a senior fellow at the Howard Hughes Medical Institute, UCLA. He completed specialty training in pediatric rheumatology and immunology at Childrens Hospital Los Angeles and directed the pediatric rheumatology program at UCLA. Dr. Rawlings has been the recipient of many awards including election to the American Society for Clinical Investigation, Association of American Physicians, and the Childrens Hospital Guild Association Endowed Chair in Pediatric Immunology Research. Dr. Rawlings also co-directs the Northwest Genome Engineering Consortium, a research program funded as part of the NIH Roadmap for Medical Research and focused on developing enzymatic reagents and delivery methods for site specific gene repair in hematopoietic stem cells. His publications include more than 90 peer-reviewed papers and many invited reviews. 

Visit website: https://www.seattlechildrens.org/directory/david-j-rawlings/

See also: Health Organisation Seattle Children's - Children's hospital in Washington

Details last updated 17-Jun-2020

David Rawlings News

Phase 1 clinical trial for type 1 diabetes cell therapy comes closer

Medical Xpress - 03-Jun-2020

A world-first novel technology to treat the disease is now within reach

Read more...